SG Americas Securities LLC Increases Stock Holdings in Accuray Incorporated (NASDAQ:ARAY)

SG Americas Securities LLC lifted its stake in shares of Accuray Incorporated (NASDAQ:ARAY) by 28.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 45,862 shares of the medical equipment provider’s stock after buying an additional 10,046 shares during the period. SG Americas Securities LLC’s holdings in Accuray were worth $130,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the stock. BlackRock Inc. lifted its holdings in Accuray by 1.5% during the first quarter. BlackRock Inc. now owns 7,749,993 shares of the medical equipment provider’s stock worth $25,651,000 after acquiring an additional 114,036 shares during the period. Neuberger Berman Group LLC lifted its holdings in Accuray by 8.0% during the third quarter. Neuberger Berman Group LLC now owns 5,246,160 shares of the medical equipment provider’s stock worth $10,905,000 after acquiring an additional 387,772 shares during the period. Vanguard Group Inc. lifted its holdings in Accuray by 1.0% during the third quarter. Vanguard Group Inc. now owns 5,223,856 shares of the medical equipment provider’s stock worth $14,209,000 after acquiring an additional 53,054 shares during the period. Renaissance Technologies LLC lifted its holdings in Accuray by 17.6% during the second quarter. Renaissance Technologies LLC now owns 3,671,907 shares of the medical equipment provider’s stock worth $7,197,000 after acquiring an additional 549,523 shares during the period. Finally, State Street Corp lifted its holdings in Accuray by 5.8% during the first quarter. State Street Corp now owns 3,464,776 shares of the medical equipment provider’s stock worth $11,468,000 after acquiring an additional 190,768 shares during the period. Hedge funds and other institutional investors own 64.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on ARAY. Roth Mkm began coverage on Accuray in a report on Tuesday, February 13th. They set a “buy” rating and a $9.00 price target on the stock. Roth Capital restated a “buy” rating on shares of Accuray in a research note on Tuesday, February 13th. Finally, TheStreet lowered Accuray from a “c-” rating to a “d+” rating in a research note on Wednesday, February 14th. One research analyst has rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $8.25.

Accuray Stock Performance

Shares of ARAY opened at $2.19 on Thursday. The firm has a market cap of $217.18 million, a PE ratio of -14.60 and a beta of 1.44. The stock’s fifty day moving average price is $2.56 and its two-hundred day moving average price is $2.67. The company has a debt-to-equity ratio of 3.53, a current ratio of 1.58 and a quick ratio of 0.84. Accuray Incorporated has a 1 year low of $2.17 and a 1 year high of $4.30.

Accuray (NASDAQ:ARAY) last issued its earnings results on Wednesday, January 31st. The medical equipment provider reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.05). The firm had revenue of $107.24 million during the quarter, compared to the consensus estimate of $107.11 million. Accuray had a negative net margin of 3.25% and a negative return on equity of 28.11%. During the same quarter in the previous year, the firm earned ($0.02) earnings per share. On average, equities research analysts forecast that Accuray Incorporated will post -0.07 EPS for the current year.

Accuray Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.